Syneos Health, Inc. (SYNH)
| Market Cap | 4.84B |
| Revenue (ttm) | 5.42B |
| Net Income (ttm) | 278.12M |
| Shares Out | 102.65M |
| EPS (ttm) | 2.61 |
| PE Ratio | 18.07 |
| Forward PE | 8.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 739,526 |
| Open | 47.69 |
| Previous Close | 47.46 |
| Day's Range | 47.11 - 49.42 |
| 52-Week Range | 46.24 - 104.18 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 79.05 (+67.7%) |
| Earnings Date | Nov 1, 2022 |
About SYNH
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, ... [Read more...]
Financial Performance
In 2021, Syneos Health's revenue was $5.21 billion, an increase of 18.05% compared to the previous year's $4.42 billion. Earnings were $234.83 million, an increase of 21.81%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for SYNH stock is "Buy." The 12-month stock price forecast is 79.05, which is an increase of 67.66% from the latest price.
News
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.
Syneos Health to Present at the 2022 Baird Global Healthcare Conference
MORRISVILLE, N.C, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michell...
physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study i...
CHICAGO--(BUSINESS WIRE)-- #AI--A leader in continuous remote patient monitoring and data analytics, physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, c...
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Syneos Health (SYNH) Beats Q2 Earnings Estimates
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health Reports Second Quarter 2022 Results
MORRISVILLE, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today reported financial results for the three and s...
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health Schedules Second Quarter 2022 Earnings Call for Tuesday, August 2, 2022
MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial resu...
Syneos Health (SYNH) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
Syneos Health to Present at Upcoming Investor Conferences
MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present a...
Syneos Health Leaders Recognized by HBA
Healthcare Businesswomen's Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry Impact Healthcare Businesswomen's Association Spotlights Kasey Boynton and Feni Komline for Biopha...
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
Syneos Health Shares Jump On Better Than Expected Q1 Earnings, FY22 Outlook
Syneos Health Inc's (NASDAQ: SYNH) Q1 revenue increased 10.5% on a reported basis and 11.7% on a constant currency (CC) basis to $1.34 billion, beating the consensus of $1.32 billion. Clinical Solutions...
Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates
Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health Names Michelle Keefe as Next Chief Executive Officer
Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles
Syneos Health Promotes Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice Pr...
MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior inter...
Syneos Health Schedules First Quarter 2022 Earnings Call for Friday, April 29th, 2022
MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will ...
Should Value Investors Pick Syneos Health (SYNH) Stock Now?
Let's see if Syneos Health, Inc. (SYNH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Here's Why You Should Retain Syneos Health (SYNH) For Now
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.
4 Stocks in Spotlight With AI Making Inroads in MedTech
MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Syneos Health (SYNH) Q4 Earnings Beat Estimates
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?